Implications of insulin-like growth factor-I for prostate cancer therapies
- PMID: 19183230
- DOI: 10.1111/j.1442-2042.2008.02224.x
Implications of insulin-like growth factor-I for prostate cancer therapies
Abstract
In the last decade, abundant evidence has suggested that the insulin-like growth factor (IGF) family comprises a multi-component network of molecules involved in the regulation of both physiological and pathological growth processes in the prostate. The IGF axis plays an important role in the tumorigenesis and neoplastic growth of prostate cancer. Epidemiological observations indicate that circulating IGF-I levels are positively associated with increased risk of prostate cancer. Activation of IGF-I receptor (IGF-IR) by IGF-I has mitogenic and anti-apoptotic effects on normal and malignant prostate cells. Therapeutic alternatives in men with progressive prostate cancer after androgen ablation are very limited and more effective therapies are needed for such patients. Inactivation of the IGF-I axis represents a potential _target to treat androgen-independent prostate cancer. This review addresses epidemiological studies of IGF-I and therapeutic strategies including reduction of IGF-I levels, inhibition of IGF-IR and the signaling mechanisms involved.
Similar articles
-
Insulin-Like Growth Factor (IGF) family and prostate cancer.Crit Rev Oncol Hematol. 2006 May;58(2):124-45. doi: 10.1016/j.critrevonc.2005.10.003. Epub 2006 Jan 18. Crit Rev Oncol Hematol. 2006. PMID: 16387509 Review.
-
Interaction of IGF signaling and the androgen receptor in prostate cancer progression.J Cell Biochem. 2006 Oct 1;99(2):392-401. doi: 10.1002/jcb.20929. J Cell Biochem. 2006. PMID: 16639715 Review.
-
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).Cancer Res. 2001 Aug 15;61(16):6276-80. Cancer Res. 2001. PMID: 11507082
-
Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.Cancer Res. 2004 Dec 1;64(23):8620-9. doi: 10.1158/0008-5472.CAN-04-2446. Cancer Res. 2004. PMID: 15574769
-
Novel insights into the implication of the IGF-1 network in prostate cancer.Trends Mol Med. 2005 Feb;11(2):52-5. doi: 10.1016/j.molmed.2004.12.005. Trends Mol Med. 2005. PMID: 15694866 Review.
Cited by
-
Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts.Int J Mol Sci. 2013 Jul 3;14(7):13782-95. doi: 10.3390/ijms140713782. Int J Mol Sci. 2013. PMID: 23823800 Free PMC article.
-
Metformin: A Bridge between Diabetes and Prostate Cancer.Front Oncol. 2017 Oct 11;7:243. doi: 10.3389/fonc.2017.00243. eCollection 2017. Front Oncol. 2017. PMID: 29075616 Free PMC article. Review.
-
Insulin-like growth factor receptor-1 (IGF-IR) as a _target for prostate cancer therapy.Cancer Metastasis Rev. 2014 Sep;33(2-3):607-17. doi: 10.1007/s10555-013-9482-0. Cancer Metastasis Rev. 2014. PMID: 24414227 Free PMC article. Review.
-
Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts.Prostate. 2012 Mar;72(4):437-49. doi: 10.1002/pros.21445. Epub 2011 Jul 7. Prostate. 2012. PMID: 21739465 Free PMC article.
-
Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474.Cancer Sci. 2015 Feb;106(2):171-8. doi: 10.1111/cas.12582. Epub 2015 Jan 16. Cancer Sci. 2015. PMID: 25483727 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
